Phexxi Efficacy with Perfect Use
With perfect use, Phexxi has not been adequately studied or reported in clinical trials, as the pivotal studies only evaluated typical use with a Pearl Index of 27.5, which translates to approximately 27.5 pregnancies per 100 woman-years. 1
Key Efficacy Data
The FDA-approved labeling for Phexxi does not provide a separate perfect use failure rate 1. The clinical trial data available shows:
- Typical use Pearl Index: 27.5 (cumulative 6-7 cycle pregnancy rate of 4.1-13.65%) 2
- This places Phexxi's efficacy substantially lower than most other contraceptive methods
- For context, spermicides (the closest comparable method) have typical use failure rates of 28% and perfect use failure rates of 18% per year 3
Critical Clinical Context
The absence of perfect use data is a significant limitation because:
- The pivotal trial (AMP002) was an open-label, single-arm study without a control group 1
- All enrolled subjects used Phexxi as their primary contraceptive method, representing real-world typical use
- No separate analysis distinguished perfect versus imperfect use patterns
Practical Implications for Counseling
Given the available evidence, you should counsel patients that:
- Phexxi is considerably less effective than hormonal contraceptives, IUDs, or implants (which have failure rates <1% with typical use)
- The method requires application immediately before or up to one hour before each act of intercourse 1
- If intercourse occurs more than once within an hour, an additional dose must be applied 1
- Even with meticulous adherence, efficacy is likely limited by the inherent mechanism of pH modulation rather than user error alone
When to Consider Phexxi
This method may be appropriate for patients who:
- Cannot or will not use hormonal contraception
- Desire a non-hormonal, user-controlled option
- Accept the higher pregnancy risk (approximately 1 in 4 chance per year with typical use)
- Are using it as backup to barrier methods like condoms 1
The lack of perfect use data means you cannot reassure patients that "perfect" application will substantially improve efficacy beyond the reported 27.5 Pearl Index.